CAMBRIDGE, Mass. — Vyome Holdings said it has successfully capitalized all funding requirements for its VT-1953 Phase 3 clinical study, providing sufficient liquidity to support the release of initial Phase 3 interim efficacy results for its malignant fungating wounds program.
The company said the funding was completed using its existing at-the-market facility, allowing Vyome to avoid warrants and limit dilution to shareholders. The capital raised is expected to cover the estimated costs required to reach interim Phase 3 results, anticipated in mid-2027.
All additional funds were raised on Jan. 27, 2026, through the sale of 1,089,045 common shares at an average price of $5.00 per share. The price represented a 59.2 percent premium to the prior day’s closing price of $3.11. Net proceeds totaled approximately $5.29 million.
Vyome said the transaction resulted in approximately 15 percent dilution to existing shareholders, bringing total common shares issued and outstanding to 7,008,882 as of Jan. 29, 2026. As of that date, the company reported cash on hand of $9.5 million.
“We have always been focused on shareholder value and are extremely pleased to report we have successfully funded our most important project’s estimated costs until interim findings anticipated in mid-2027,” said Krishna Gupta, chairman of Vyome. “Inflammation is one of the biggest problems facing the world, and symptoms of MFW are our first target, via VT-1953, in immune-inflammation. As we recently disclosed in an independent valuation report, VT-1953 is estimated by a third party to be worth $1 billion upon anticipated completion of the Phase 3 clinical trials in approximately 18 months.”
Gupta added that securing the funding with limited dilution reflected the company’s focus on shareholder value. “To have achieved this funding at relatively minimal dilution – while turning down funding options at much higher dilution – shows our focus on shareholder value,” he said.
“In the last week, we were aggressively solicited by multiple investment banks offering larger blocks of capital, but with warrants, investor rights, and other strings attached that we believe would have been harmful to our shareholders,” said Venkat Nelabhotla, chief executive officer of Vyome. “Instead, we sourced the absolute lowest cost of capital, with no warrants, and we believe that we are now very well-funded to execute on the plan we have previously laid out to the market on getting VT-1953 through the interim results of Phase 3 clinical trials.”
Nelabhotla said the company expects to provide additional updates on its progress in the coming months.
